Canopy Growth tops Q1 estimates on strong Canadian adult-use sales

Canopy Growth Corporation reported better-than-expected Q1 2026 financial results, with revenue up 9% year-over-year to C$72.1 million, significantly exceeding analyst estimates of C$64.5 million. This growth was primarily fueled by a 43% surge in Canadian adult-use cannabis sales and a 13% increase in Canadian medical sales. The company also substantially narrowed its net loss to C$41.5 million (C$0.22 per share), aligning with consensus, which led to an over 11% jump in its shares, signaling improving operational performance and investor confidence in its core segments.

Analysis

Canopy Growth Corporation (CGC) delivered a strong fiscal Q1 2026 earnings report, significantly beating revenue expectations and signaling improving fundamentals in its core markets. Total revenue grew 9% year-over-year to C$72.1 million, starkly contrasting with analyst consensus that had forecasted a decline to C$64.5 million. This outperformance was primarily fueled by a 43% surge in the Canadian adult-use cannabis segment and a solid 13% increase in Canadian medical sales, indicating robust consumer demand and market share gains domestically. However, this strength was partially offset by a notable revenue drop in the Storz & Bickel brand, which fell to $15.2 million from $20.1 million year-over-year, attributed to challenging comparisons and consumer economic pressures. On the profitability front, the company made substantial progress, narrowing its net loss to C$41.5 million from C$127.1 million in the prior year, with the resulting loss per share of C$0.22 meeting consensus estimates. The market's reaction was decisively positive, with an 11% share price increase, reflecting investor confidence in the top-line momentum and the company's progress toward operational stability.

Key Decisions for Investors

• The robust 43% growth in Canadian adult-use cannabis sales signals a strengthening core business, warranting a reassessment of the company's near-term revenue potential.
• Investors should closely monitor the Storz & Bickel segment, as its revenue decline attributed to consumer economic uncertainty presents a material risk that could offset gains in the core cannabis operations.
• While the narrowing net loss is encouraging, investors should scrutinize future earnings for continued progress on the path to profitability, as this remains a critical catalyst for long-term value creation.
• Given the sharp 11% post-earnings stock appreciation, it is prudent to assess whether the improved outlook is now fully priced in or if the momentum in the Canadian market can support further upside.